Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice
Varun Pathak, Victor A. Gault, Peter R. Flatt, et al.
Molecular and Cellular Endocrinology (2014) Vol. 401, pp. 120-129
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1318
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 221
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr Mróz, Brian Finan, Vasily M. Gelfanov, et al.
Molecular Metabolism (2018) Vol. 20, pp. 51-62
Open Access | Times Cited: 177
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 3
Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
Alexander H. Sparre‐Ulrich, L. Hansen, Berit Svendsen, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 1, pp. 27-38
Open Access | Times Cited: 101
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Van B. Lu, Fiona M. Gribble, Frank Reimann
Nutrients (2021) Vol. 13, Iss. 3, pp. 883-883
Open Access | Times Cited: 66
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
L. Hansen, Alexander H. Sparre‐Ulrich, Mikkel Christensen, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 5, pp. 826-838
Open Access | Times Cited: 90
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A. Killion, Shu-Chen Lu, Madeline Fort, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 1-21
Open Access | Times Cited: 74
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Lærke S. Gasbjerg, M Gabe, Bolette Hartmann, et al.
Peptides (2018) Vol. 100, pp. 173-181
Closed Access | Times Cited: 73
GIP(3–30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release
Alexander H. Sparre‐Ulrich, M Gabe, Lærke S. Gasbjerg, et al.
Biochemical Pharmacology (2017) Vol. 131, pp. 78-88
Open Access | Times Cited: 70
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Berit Svendsen, Megan E. Capozzi, Jingjing Nui, et al.
Molecular Metabolism (2019) Vol. 32, pp. 44-55
Open Access | Times Cited: 51
Incretins
Tongzhi Wu, Christopher K. Rayner, Michael Horowitz
Handbook of experimental pharmacology (2015), pp. 137-171
Closed Access | Times Cited: 50
GIP analogues and the treatment of obesity-diabetes
Clifford J. Bailey
Peptides (2019) Vol. 125, pp. 170202-170202
Closed Access | Times Cited: 45
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Bin Yang, Vasily M. Gelfanov, Kimberley El, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101638-101638
Open Access | Times Cited: 27
High fat-fed diabetic mice present with profound alterations of the osteocyte network
Guillaume Mabilleau, Rodolphe Perrot, Peter R. Flatt, et al.
Bone (2016) Vol. 90, pp. 99-106
Open Access | Times Cited: 42
Molecular interactions of full-length and truncated GIP peptides with the GIP receptor – A comprehensive review
M Gabe, Wijnand J. C. van der Velden, Florent X. Smit, et al.
Peptides (2019) Vol. 125, pp. 170224-170224
Open Access | Times Cited: 36
Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice
Varun Pathak, Srividya Vasu, Victor A. Gault, et al.
Diabetologia (2015) Vol. 58, Iss. 9, pp. 2144-2153
Open Access | Times Cited: 37
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Kerstin Stemmer, Brian Finan, Richard D. DiMarchi, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 34-53
Closed Access | Times Cited: 32
Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2;ROSA26-eYFP mice
Dipak Sarnobat, R. Charlotte Moffett, Victor A. Gault, et al.
Peptides (2019) Vol. 125, pp. 170205-170205
Open Access | Times Cited: 31
Development of a long-acting unbiased GIP receptor agonist for studies of GIP’s role in bone metabolism
Esther Karen Tordrup, Sarina Gadgaard, Johanne Agerlin Windeløv, et al.
Biochemical Pharmacology (2025), pp. 116893-116893
Closed Access
Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
Sara Baldassano, Lærke S. Gasbjerg, Hüsün Sheyma Kizilkaya, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 28
CNS-targeting pharmacological interventions for the metabolic syndrome
Kerstin Stemmer, Timo D. Müller, Richard D. DiMarchi, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 10, pp. 4058-4071
Open Access | Times Cited: 27
Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties
Finbarr O’Harte, Vadivel Parthsarathy, Christopher Hogg, et al.
Biochemical Pharmacology (2017) Vol. 146, pp. 165-173
Open Access | Times Cited: 27
Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
Jennifer D. Könitzer, Shreya Pramanick, Qi Pan, et al.
mAbs (2017) Vol. 9, Iss. 3, pp. 536-549
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top